Critical Outcome Techno
Description Critical Outcome Technologies Inc. operates as a biotechnology company in Canada. It focuses on applying its proprietary computer based technology, CHEMSAS, to identify, profile, optimize, select, and validate commercially viable drug candidates at the earliest stage of preclinical drug development. The company is developing a pipeline of drug candidates for the treatment of small cell lung, adult myelogenous leukemia (AML), ovarian, endometrial, pancreatic, brain, breast, and colon cancers, as well as human immunodeficiency virus (HIV), Alzheimers disease, and multiple sclerosis. Its lead compound COTI-2, an oncology molecule in Phase I clinical trial, acts by inhibiting protein kinase B phosphorylation that leads to caspase-9 activation in cancer cells resulting in tumor cell death. Critical Outcome Technologies Inc. is headquartered in London, Canada. To view the detailed information, you need to SUBSCRIBE with us. |
 |